As common—and costly—as off-label prescribing is in oncology, it is poorly understood. It is, by nature, hard to study. Yet it is clear that the practice is changing. Skyrocketing drug costs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results